Moderna, Inc.

MRNA

US60770K1079

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 03:16:00 2025-07-09 pm EDT			5-day change	1st Jan Change
32.71 ^USD	+0.52%		+7.69%	-21.57%

Jul. 08	Wall St stocks edge lower as investors look for tariff clarity	RE
Jul. 08	Wall St is mixed as investors monitor Trump's latest tariff moves	RE

Roivant Sciences Unit, Arbutus File Lawsuits Against Moderna for Alleged Patent Infringement

Published on 03/03/2025 at 10:07, updated on 03/03/2025 at 10:08

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Moderna, Inc.

Wall St stocks edge lower as investors look for tariff clarity	Jul. 08	RE
Wall St is mixed as investors monitor Trump's latest tariff moves	Jul. 08	RE
US CDC ends emergency bird flu response as infections decline	Jul. 07	RE
US CDC accepts ousted vaccine panel's recommendations for RSV, meningococcal shots	Jul. 02	RE
US CDC accepts ousted vaccine panel's recommendations for RSV, meningococcal shots	Jul. 02	RE
Moderna, Inc. Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-29-2025 10:00 AM	Jul. 01
Health Care Up as Budget Bill Fears Ease -- Health Care Roundup	Jun. 30	DJ
Moderna, Inc.(NasdaqGS:MRNA) added to Russell Midcap Value Index	Jun. 30	CI
Sector Update: Health Care Stocks Higher Late Afternoon	Jun. 30	MT
Sector Update: Health Care Stocks Advance Monday Afternoon	Jun. 30	MT
Sector Update: Health Care	Jun. 30	MT
Top Midday Stories: Hewlett Packard, Juniper Settle Antitrust Suit With DOJ; Home Depot Unit Acquires GMS for $5.5 Billion	Jun. 30	MT
Global markets live: KKR, Moderna, Nvidia, Boeing, UBS…	Jun. 30
Moderna Says Flu Vaccine Candidate More Effective Than Standard Licensed Shots	Jun. 30	MT
Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday	Jun. 30	MT
Sector Update: Health Care	Jun. 30	MT
Exchange-Traded Funds, Equity Futures Edge Higher Pre-Bell Monday Amid Hopes of Smoother Canada Relations	Jun. 30	MT
Moderna says flu shot more effective than rival GSK in late-stage study	Jun. 30	RE
Moderna Reports Positive Data From Phase 3 Study of mRNA-1010 Seasonal Influenza Vaccine Candidate	Jun. 30	MT
Moderna: positive efficacy data for influenza	Jun. 30	CF
Moderna's influenza vaccine superior to licensed shot in study	Jun. 30	RE
Moderna, Inc.(NasdaqGS:MRNA) dropped from Russell Top 200 Value Index	Jun. 30	CI
Moderna, Inc.(NasdaqGS:MRNA) added to Russell Midcap Index	Jun. 29	CI
Moderna, Inc.(NasdaqGS:MRNA) dropped from Russell Top 200 Index	Jun. 29	CI
Moderna, Inc.(NasdaqGS:MRNA) dropped from Russell Top 200 Value Benchmark	Jun. 29	CI

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (97.4%); - grant revenue (1.4%); - revenue from collaboration agreements (1.2%). At the end of 2023, the group possessed a portfolio of 41 products in clinical development, of which 6 in phase III, 12 in phase II and 18 in phase I, and 5 products in preclinical development. Net sales are distributed geographically as follows: the United States (27.7%), Europe (19.8%) and other (52.5%).

Employees

5,800

Sector

Pharmaceuticals

Calendar

Jul. 30 - Q2 2025 Earnings Release (Projected)

More about the company